Lupvindol Biosciences Ltd., a pioneer in steroid-sparing therapies for inflammation and pain, today announced that the U.S. Food and Drug Administration’s Center for Veterinary Medicine (FDA/CVM) has opened an Investigational New Animal Drug (INAD) file for its patented fixed-dose combination therapy.